
|Articles|April 24, 2022
Successful phase 2 trial, Aerie Pharmaceuticals, Inc.’s dry eye candidate advancing to phase 3
Author(s)David Hutton
David Wirta, MD, Medical Director for the Eye Research Foundation, Inc., presents the data of Aerie Pharmaceuticals, Inc.’s novel dry eye product candidate, AR-15512 (0.003%). The successful phase 2 results has propelled the product into phase 3 trials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis
2
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
3
New optoretinography technique allows direct measurement of rod function in vivo
4
Long-lived Greenland sharks may point to new approaches for retinal disease
5












































